TetraLogic Pharmaceuticals (TLOG) Announces Preclinical Data Indicating Birinapant's Breadth Of Activity In Models Of Infectious Disease
6/9/2014 9:20:24 AM
MALVERN, Pa., June 9, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced results from its collaboration with the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, indicating that SMAC mimetics, including TetraLogic's lead compound birinapant, may have broad applicability in the treatment of infectious disease.
Help employers find you! Check out all the jobs and post your resume.
comments powered by